Close Menu

NEW YORK – Twist Bioscience said Tuesday after the close of the market that it intends to sell up to $100 million of its common stock in an underwritten public offering.

Twist said it plans to use the proceeds to invest in its research and development organization, including pharmaceutical biologics drug discovery and DNA data storage; to scale its next-generation sequencing commercial operations; and to expand its production capacity. The company will also use the funds for working capital and general corporate purposes. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.